Fortress Biotech to Participate in 36th Annual ROTH Conference
12 März 2024 - 1:30PM
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative
biopharmaceutical company focused on efficiently acquiring,
developing and commercializing or monetizing promising therapeutic
products and product candidates, today announced that Lindsay A.
Rosenwald, M.D., Chairman, President and Chief Executive Officer,
will participate in a fireside chat at the 36th Annual ROTH
Conference on Monday, March 18, 2024, at 2:00 p.m. PT in Dana
Point, California. The Company will also attend one-on-one meetings
during the conference.
A webcast of the fireside chat will be available
on the Events page under the News & Media section of Fortress’
website: www.fortressbiotech.com for approximately 30 days
following the meeting.
About Fortress BiotechFortress
Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical
company focused on efficiently acquiring, developing and
commercializing or monetizing promising therapeutic products and
product candidates. The company has seven marketed prescription
pharmaceutical products and over 25 programs in development at
Fortress, at its majority-owned and majority-controlled partners
and subsidiaries and at partners and subsidiaries it founded and in
which it holds significant minority ownership positions. Such
product candidates span six large-market areas, including oncology,
rare diseases and gene therapy, which allow it to create value for
shareholders. Fortress advances its diversified pipeline through a
streamlined operating structure that fosters efficient drug
development. The Fortress model is focused on leveraging its
significant biopharmaceutical industry expertise and network to
further expand the company’s portfolio of product opportunities.
Fortress has established partnerships with some of the world’s
leading academic research institutions and biopharmaceutical
companies to maximize each opportunity to its full potential,
including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center,
St. Jude Children’s Research Hospital, Nationwide Children’s
Hospital and Sentynl. For more information, visit
www.fortressbiotech.com.
Company Contact:Jaclyn JaffeFortress Biotech,
Inc.(781) 652-4500ir@fortressbiotech.com
Media Relations Contact:Tony Plohoros6
Degrees(908) 591-2839tplohoros@6degreespr.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
Von Jun 2023 bis Jun 2024